title: SLIT improves cedar pollinosis by restoring IL-10 production from Tr1 and Monocytes∼IL-10 productivity is critical for becoming allergic∼.
abstract: BACKGROUND
  Allergen-specific immunotherapy (SIT) is currently used for several allergic disorders and IL-10-producing regulatory T cells (Tr1) induced by SIT suppress allergic reactions. We investigated the relation between IL-10 production and acquiring allergy.
  
  
  METHODS
  A prospective study was undertaken to evaluate the effect of SIT on IL-10 production in T cells and other cell fractions in children with pollinosis. In addition, blood samples were collected from non-allergic healthy controls and patients with pollinosis to compare the levels of IL-10 production. PBMC were cultured with pollen peptides or control allergens, and the IL-10 production from monocyte and CD4 T cell was analyzed.
  
  
  RESULTS
  Monocytes and CD4 T cells from SIT group of patients produced high levels of IL-10, suggesting that the induction of IL-10 is essential for inducing T cell tolerance. IL-10 production from monocytes and T cells was significantly increased in non-allergic controls compared to patients with pollinosis. This high IL-10 production was observed even when PBMC were stimulated with antigens other than pollen peptides.
  
  
  CONCLUSIONS
  IL-10 is critical for induction of specific T cell tolerance, and increased production of IL-10 by monocytes and T cells during inflammatory responses or after SIT may influence effector cells in allergy. Present data implicates that the low productivity of IL-10 by monocytes and T cells is closely related with sensitivity to multiple allergens, and resistance to allergic diseases. Augmentation of constitutive IL-10 production from immune system is a potential therapeutic approach for allergic disorders.
authors.affiliation: Department of Dermatology, Mie University Graduate School of Medicine, Japan. yamake@clin.medic.mie-u.ac.jp
authors.forename: Kei-ichi
authors.initials: K
authors.lastname: Yamanaka
authors.forename: Atsushi
authors.initials: A
authors.lastname: Yuta
authors.forename: Masato
authors.initials: M
authors.lastname: Kakeda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kitagawa
authors.forename: Hitomi
authors.initials: H
authors.lastname: Ogihara
authors.forename: Esteban C
authors.initials: EC
authors.lastname: Gabazza
authors.forename: Kimihiro
authors.initials: K
authors.lastname: Okubo
authors.forename: Ichiro
authors.initials: I
authors.lastname: Kurokawa
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Takeuchi
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Mizutani
mesh_terms: D000293:Adolescent; D000485:Allergens / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D028203:Cedrus / Q000276:immunology*; D002648:Child; D003888:Desensitization, Immunologic; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000276:immunology*; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D009000:Monocytes / Q000276:immunology*; D011058:Pollen / Q000276:immunology; D011446:Prospective Studies; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology* / Q000628:therapy*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000485:Allergens; D016753:Interleukin-10